Treatment Response Prediction System of mCRC Patients Based on CTC

Launched by FUDAN UNIVERSITY · Jun 2, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on improving treatment for patients with advanced colorectal cancer that has spread to the liver. Researchers want to understand how to detect circulating tumor cells (CTCs) in the blood at different times during treatment. By studying these cells, they hope to create a system that can predict how well patients will respond to treatments, ultimately helping doctors make more informed decisions about patient care.

To participate in this trial, patients should be between 18 and 80 years old and have been diagnosed with colorectal cancer that has spread primarily to the liver, with any other spread limited to the lungs. Participants need to be in relatively good health, with a life expectancy of at least three months, and must provide consent to join the study. While the trial is not yet recruiting participants, it aims to gather important data that could lead to better treatment options for those facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-80 years;
• • histologically proven colorectal liver metastasis
• • With liver-dominant disease (extrahepatic metastases limited to lung metastases)
• • ECOG 0-1
• • A life expectancy of ≥ 3 months
• • Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3
• • Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl
• • Written informed consent for participation in the trial.
• Exclusion Criteria:
• • Other previous malignancy within 5 years
• • Have metastases other than liver and lung metastases
• • Receiving any treatment before first blood collection